{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:15:14Z","timestamp":1789758914025,"version":"4.0.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s11926-020-00921-8","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T19:29:02Z","timestamp":1593199742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Therapeutic Options and Cost-Effectiveness for Rheumatoid Arthritis Treatment"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2232-0326","authenticated-orcid":false,"given":"Alexandros A.","family":"Drosos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9383-5722","authenticated-orcid":false,"given":"Eleftherios","family":"Pelechas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7212-0533","authenticated-orcid":false,"given":"Evripidis","family":"Kaltsonoudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5193-2284","authenticated-orcid":false,"given":"Paraskevi V.","family":"Voulgari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"921_CR1","doi-asserted-by":"crossref","unstructured":"Pelechas E, Kaltsonoudis E, Voulgari PV, Drosos AA. Rheumatoid arthritis. In: Illustrated Handbook of Rheumatic and Musculo-Skeletal Diseases. Switzerland: Springer, Cham; 2019, p. 45\u201376.","DOI":"10.1007\/978-3-030-03664-5_3"},{"key":"921_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/nrrheum.2013.168","volume":"10","author":"GR Burmester","year":"2014","unstructured":"Burmester GR, Feist E, D\u00f6rner T. Emerging cell and cytokine targets in rheumatoid arthritis. Nat Rev Rheumatol. 2014;10:77\u201388. https:\/\/doi.org\/10.1038\/nrrheum.2013.168.","journal-title":"Nat Rev Rheumatol"},{"key":"921_CR3","doi-asserted-by":"publisher","first-page":"E938","DOI":"10.3390\/jcm8070938","volume":"8","author":"BM K\u00f6hler","year":"2019","unstructured":"K\u00f6hler BM, G\u00fcnther J, Kaudewitz D, Lorenz HM. Current therapeutic options in the treatment of rheumatoid arthritis. J Clin Med. 2019;8:E938. https:\/\/doi.org\/10.3390\/jcm8070938.","journal-title":"J Clin Med"},{"key":"921_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1741-7015-11-88","volume":"11","author":"Z Rosman","year":"2013","unstructured":"Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med. 2013;11:88. https:\/\/doi.org\/10.1186\/1741-7015-11-88.","journal-title":"BMC Med"},{"key":"921_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheum. 2016;68:1\u201326. https:\/\/doi.org\/10.1002\/art.39480.","journal-title":"Arthritis Rheum"},{"key":"921_CR6","doi-asserted-by":"publisher","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;pii:annrheumdis-2019-216655. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655.","DOI":"10.1136\/annrheumdis-2019-216655"},{"key":"921_CR7","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/ard.2009.126714","volume":"69","author":"M Schoels","year":"2010","unstructured":"Schoels M, Wong J, Scott DL, Zink A, Richards P, Landew\u00e9 R, et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:995\u20131003. https:\/\/doi.org\/10.1136\/ard.2009.126714.","journal-title":"Ann Rheum Dis"},{"key":"921_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.7326\/M17-1176","volume":"167","author":"E Losina","year":"2017","unstructured":"Losina E, Katz JN. Improvement at any cost? The art and science of choosing treatment strategies for rheumatoid arthritis. Ann Intern Med. 2017;167:55\u20136. https:\/\/doi.org\/10.7326\/M17-1176.","journal-title":"Ann Intern Med"},{"key":"921_CR9","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.3899\/jrheum.101327","volume":"38","author":"JC Tosh","year":"2011","unstructured":"Tosh JC, Wailoo AJ, Scott DL, Deighton CM. Cost-effectiveness of combination nonbiologic disease-modifying antirheumatic drug strategies in patients with early rheumatoid arthritis. J Rheumatol. 2011;38:1593\u2013600. https:\/\/doi.org\/10.3899\/jrheum.101327.","journal-title":"J Rheumatol"},{"key":"921_CR10","doi-asserted-by":"publisher","unstructured":"Wailoo A, Hern\u00e1ndez Alava M, Scott IC, Ibrahim F, Scott DL. Cost-effectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis. Rheumatology (Oxford). 2014;53:1773\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/keu039.","DOI":"10.1093\/rheumatology\/keu039"},{"key":"921_CR11","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1093\/rheumatology\/kew321","volume":"55","author":"PH de Jong","year":"2016","unstructured":"de Jong PH, Hazes JM, Buisman LR, Barendregt PJ, van Zeben D, van der Lubbe PA, et al. Best cost-effectiveness and worker productivity with initial triple-DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial. Rheumatology (Oxford). 2016;55:2138\u201347.","journal-title":"Rheumatology (Oxford)"},{"key":"921_CR12","doi-asserted-by":"publisher","first-page":"E1237","DOI":"10.3390\/jcm8081237","volume":"8","author":"AA Drosos","year":"2019","unstructured":"Drosos AA, Pelechas E, Voulgari PV. Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs? J Clin Med. 2019;8:E1237. https:\/\/doi.org\/10.3390\/jcm8081237.","journal-title":"J Clin Med"},{"key":"921_CR13","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s10067-020-05001-x","volume":"39","author":"AA Drosos","year":"2020","unstructured":"Drosos AA, Pelechas E, Voulgari PV. Treatment strategies are more important than drugs in the management of rheumatoid arthritis. Clin Rheumatol. 2020;39:1363\u20138. https:\/\/doi.org\/10.1007\/s10067-020-05001-x.","journal-title":"Clin Rheumatol"},{"key":"921_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3\u201315. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207524.","journal-title":"Ann Rheum Dis"},{"key":"921_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/BF02114393","volume":"9","author":"AA Drosos","year":"1990","unstructured":"Drosos AA, Psychos D, Andonopoulos AP, Stefanaki-Nikou S, Tsianos EB, Moutsopoulos HM. Methotrexate therapy in rheumatoid arthritis. A two-year prospective follow-up. Clin Rheumatol. 1990;9:333\u201341.","journal-title":"Clin Rheumatol"},{"key":"921_CR16","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/bf02114394","volume":"9","author":"AA Drosos","year":"1990","unstructured":"Drosos AA, Karantanas AH, Psychos D, Tsampoulas C, Moutsopoulos HM. Can treatment with methotrexate influence the radiological progression of rheumatoid arthritis? Clin Rheumatol. 1990;9:342\u20135. https:\/\/doi.org\/10.1007\/bf02114394.","journal-title":"Clin Rheumatol"},{"key":"921_CR17","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/rheumatology\/33.11.1049","volume":"33","author":"CJ Haagsma","year":"1994","unstructured":"Haagsma CJ, van Riel PL, de Rooij DJ, Vree TB, Russel FJ, van't Hof MA, et al. Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy. Br J Rheumatol. 1994;33:1049\u201355. https:\/\/doi.org\/10.1093\/rheumatology\/33.11.1049.","journal-title":"Br J Rheumatol"},{"key":"921_CR18","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1093\/rheumatology\/36.10.1082","volume":"36","author":"CJ Haagsma","year":"1997","unstructured":"Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52-week clinical trial. Br J Rheumatol. 1997;36:1082\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/36.10.1082.","journal-title":"Br J Rheumatol"},{"key":"921_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(97)01300-7","volume":"350","author":"M Boers","year":"1997","unstructured":"Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997;350:309\u201318. https:\/\/doi.org\/10.1016\/S0140-6736(97)01300-7.","journal-title":"Lancet."},{"key":"921_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/art.10083","volume":"46","author":"RB Landew\u00e9","year":"2002","unstructured":"Landew\u00e9 RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination-therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002;46:347\u201356. https:\/\/doi.org\/10.1002\/art.10083.","journal-title":"Arthritis Rheum"},{"key":"921_CR21","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1136\/ard.2009.108027","volume":"69","author":"LH van Tuyl","year":"2010","unstructured":"van Tuyl LH, Boers M, Lems WF, Landew\u00e9 RB, Han H, van der Linden S, et al. Survival, comorbidities and joint damage 11 years after the COBRA combination-therapy trial in early rheumatoid arthritis. Ann Rheum Dis. 2010;69:807\u201312. https:\/\/doi.org\/10.1136\/ard.2009.108027.","journal-title":"Ann Rheum Dis"},{"key":"921_CR22","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1136\/annrheumdis-2018-214618","volume":"78","author":"PBM Poppelaars","year":"2019","unstructured":"Poppelaars PBM, van Tuyl LHD, Boers M. Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up. Ann Rheum Dis. 2019;78:586\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214618.","journal-title":"Ann Rheum Dis"},{"issue":"9164","key":"921_CR23","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/s0140-6737(98)08513-4","volume":"353","author":"T M\u00f6tt\u00f6nen","year":"1999","unstructured":"M\u00f6tt\u00f6nen T, Hannonen P, Leirisalo-Repo M, Nissil\u00e4 M, Kautiainen H, Korpela M, et al. Comparison of combination-therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet. 1999 May 8;353(9164):1568\u201373. https:\/\/doi.org\/10.1016\/s0140-6737(98)08513-4.","journal-title":"Lancet"},{"key":"921_CR24","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1002\/art.24447","volume":"60","author":"V Rantalaiho","year":"2009","unstructured":"Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, J\u00e4rvenp\u00e4\u00e4 S, Leirisalo-Repo M, et al. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination-therapy trial. Arthritis Rheum. 2009;60:1222\u201331. https:\/\/doi.org\/10.1002\/art.24447.","journal-title":"Arthritis Rheum"},{"key":"921_CR25","doi-asserted-by":"publisher","first-page":"R122","DOI":"10.1186\/ar3060","volume":"12","author":"V Rantalaiho","year":"2010","unstructured":"Rantalaiho V, Korpela M, Laasonen L, Kautiainen H, J\u00e4rvenp\u00e4\u00e4 S, Hannonen P, et al. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish rheumatoid arthritis combination-therapy trial. Arthritis Res Ther. 2010;12:R122. https:\/\/doi.org\/10.1186\/ar3060.","journal-title":"Arthritis Res Ther"},{"key":"921_CR26","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1002\/art.21405","volume":"52","author":"YP Goekoop-Ruiterman","year":"2005","unstructured":"Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52:3381\u201390. https:\/\/doi.org\/10.1002\/art.21405.","journal-title":"Arthritis Rheum"},{"key":"921_CR27","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1136\/ard.2006.068296","volume":"66","author":"YP Goekoop-Ruiterman","year":"2007","unstructured":"Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, Kerstens PJ, Grillet BA, de Jager MH, et al. Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). Ann Rheum Dis. 2007;66:1227\u201332. https:\/\/doi.org\/10.1136\/ard.2006.068296.","journal-title":"Ann Rheum Dis"},{"key":"921_CR28","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1002\/art.23449","volume":"58","author":"SA Saunders","year":"2008","unstructured":"Saunders SA, Capell HA, Stirling A, Vallance R, Kincaid W, McMahon AD, et al. Triple-therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum. 2008;58:1310\u20137. https:\/\/doi.org\/10.1002\/art.23449.","journal-title":"Arthritis Rheum"},{"key":"921_CR29","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1002\/art.34498","volume":"64","author":"LW Moreland","year":"2012","unstructured":"Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St.Clair EW, et al. A randomized comparative effectiveness study of oral triple-therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheum. 2012;64:2824\u201335. https:\/\/doi.org\/10.1002\/art.34498.","journal-title":"Arthritis Rheum"},{"key":"921_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1303006","volume":"369","author":"JR O'Dell","year":"2013","unstructured":"O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013;369:307\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1303006.","journal-title":"N Engl J Med"},{"key":"921_CR31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0140-6736(09)60944-2","volume":"374","author":"RF van Vollenhoven","year":"2009","unstructured":"van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, C\u00f6ster L, Waltbrand E, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet. 2009;374:459\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(09)60944-2.","journal-title":"Lancet"},{"key":"921_CR32","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/S0140-6736(12)60027-0","volume":"379","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2-year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet. 2012;379:1712\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(12)60027-0.","journal-title":"Lancet."},{"key":"921_CR33","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1136\/annrheumdis-2019-215304","volume":"78","author":"MM Verhoeven","year":"2019","unstructured":"Verhoeven MM, de Hair MJ, Tekstra J, Bijlsma JW, van Laar JM, Pethoe-Schramm A, et al. Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-act-early and CAMERA-II treat-to-target trials. Ann Rheum Dis. 2019;78:1333\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215304.","journal-title":"Ann Rheum Dis"},{"key":"921_CR34","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/rheumatology\/37.10.1102","volume":"37","author":"AC Verhoeven","year":"1998","unstructured":"Verhoeven AC, Bibo JC, Boers M, Engel GL, van der Linden S. Cost-effectiveness and cost-utility of combination-therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA trial group. Combinatietherapie Bij Reumato\u00efde Artritis. Br J Rheumatol. 1998;37:1102\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/37.10.1102.","journal-title":"Br J Rheumatol"},{"key":"921_CR35","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1136\/annrheumdis-2013-204788","volume":"73","author":"PH de Jong","year":"2014","unstructured":"de Jong PH, Hazes JM, Han HK, Huisman M, van Zeben D, van der Lubbe PA, et al. Randomised comparison of initial triple-DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis. 2014;73:1331\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204788.","journal-title":"Ann Rheum Dis"},{"key":"921_CR36","first-page":"409","volume":"31","author":"T Sokka","year":"2013","unstructured":"Sokka T, Haugeberg G, Asikainen J, Widding Hansen IJ, Kokko A, Rannio T, et al. Similar clinical outcomes in rheumatoid arthritis with more versus less expensive treatment strategies. Observational data from two rheumatology clinics. Clin Exp Rheumatol. 2013;31:409\u201314.","journal-title":"Clin Exp Rheumatol"},{"key":"921_CR37","doi-asserted-by":"publisher","unstructured":"Fautrel B. Economic benefits of optimizing anchor therapy for rheumatoid arthritis. Rheumatology (Oxford). 2012;51:iv21\u20136. https:\/\/doi.org\/10.1093\/rheumatology\/kes088.","DOI":"10.1093\/rheumatology\/kes088"},{"key":"921_CR38","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/art.24169","volume":"61","author":"WB van den Hout","year":"2009","unstructured":"van den Hout WB, Goekoop-Ruiterman YP, Allaart CF, de Vries-Bouwstra JK, Hazes JM, Kerstens PJ, et al. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2009;61:291\u20139. https:\/\/doi.org\/10.1002\/art.24169.","journal-title":"Arthritis Rheum"},{"key":"921_CR39","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/acr.22895","volume":"68","author":"H Jalal","year":"2016","unstructured":"Jalal H, O'Dell JR, Bridges SL Jr, Cofield S, Curtis JR, Mikuls TR, et al. Cost-effectiveness of triple-therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis. Arthritis Care Res. 2016;68:1751\u20137. https:\/\/doi.org\/10.1002\/acr.22895.","journal-title":"Arthritis Care Res"},{"key":"921_CR40","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1001\/jamainternmed.2013.7801","volume":"173","author":"JK Eriksson","year":"2013","unstructured":"Eriksson JK, Neovius M, Bratt J, Petersson IF, van Vollenhoven RF, Geborek P, et al. Biological vs. conventional combination treatment and work loss in early rheumatoid arthritis: a randomized trial. JAMA Intern Med. 2013;173:1407\u201314. https:\/\/doi.org\/10.1001\/jamainternmed.2013.7801.","journal-title":"JAMA Intern Med"},{"key":"921_CR41","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1136\/annrheumdis-2013-205060","volume":"74","author":"JK Eriksson","year":"2015","unstructured":"Eriksson JK, Karlsson JA, Bratt J, Petersson IF, van Vollenhoven RF, Ernestam S, et al. Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. Ann Rheum Dis. 2015;74:1094\u2013101. https:\/\/doi.org\/10.1136\/annrheumdis-2013-205060.","journal-title":"Ann Rheum Dis"},{"key":"921_CR42","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3899\/jrheum.160941","volume":"44","author":"MD Stevenson","year":"2017","unstructured":"Stevenson MD, Wailoo AJ, Tosh JC, Hernandez-Alava M, Gibson LA, Stevens JW, et al. The cost-effectiveness of sequences of biological disease-modifying antirheumatic drug treatment in England for patients with rheumatoid arthritis who can tolerate methotrexate. J Rheumatol. 2017;44:973\u201380. https:\/\/doi.org\/10.3899\/jrheum.160941.","journal-title":"J Rheumatol"},{"key":"921_CR43","doi-asserted-by":"publisher","first-page":"h1046","DOI":"10.1136\/bmj.h1046","volume":"350","author":"DL Scott","year":"2015","unstructured":"Scott DL, Ibrahim F, Farewell V, O'Keeffe AG, Walker D, Kelly C, et al. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. BMJ. 2015;350:h1046. https:\/\/doi.org\/10.1136\/bmj.h1046.","journal-title":"BMJ."},{"key":"921_CR44","doi-asserted-by":"publisher","first-page":"8","DOI":"10.7326\/M16-0713","volume":"167","author":"N Bansback","year":"2017","unstructured":"Bansback N, Phibbs CS, Sun H, O'Dell JR, Brophy M, Keystone EC, et al. Triple-therapy versus biologic therapy for active rheumatoid arthritis: a cost-effectiveness analysis. Ann Intern Med. 2017;167:8\u201316. https:\/\/doi.org\/10.7326\/M16-0713.","journal-title":"Ann Intern Med"},{"key":"921_CR45","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/acr.23830","volume":"72","author":"A Patel","year":"2020","unstructured":"Patel A, Heslin M, Scott DL, Stringer D, Birrell F, Ibrahim F. Cost-effectiveness of combination disease-modifying antirheumatic drugs versus tumor necrosis factor inhibitors in active rheumatoid arthritis: a pragmatic, randomized, multicenter trial. Arthritis Care Res. 2020;72:334\u201342. https:\/\/doi.org\/10.1002\/acr.23830.","journal-title":"Arthritis Care Res"},{"key":"921_CR46","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1136\/annrheumdis-2015-208317","volume":"75","author":"W Kievit","year":"2016","unstructured":"Kievit W, van Herwaarden N, van den Hoogen FH, van Vollenhoven RF, Bijlsma JW, van den Bemt BJ, et al. Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Ann Rheum Dis. 2016;75:1939\u201344. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208317.","journal-title":"Ann Rheum Dis"},{"key":"921_CR47","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/j.clinthera.2016.09.016","volume":"38","author":"SK Park","year":"2016","unstructured":"Park SK, Park SH, Lee MY, Park JH, Jeong JH, Lee EK. Cost-effectiveness analysis of treatment sequence initiating with etanercept compared with leflunomide in rheumatoid arthritis: impact of reduced etanercept cost with patent expiration in South Korea. Clin Ther. 2016;38:2430\u20132446.e3. https:\/\/doi.org\/10.1016\/j.clinthera.2016.09.016.","journal-title":"Clin Ther"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-020-00921-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-020-00921-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-020-00921-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T23:34:57Z","timestamp":1624664097000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-020-00921-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["921"],"URL":"https:\/\/doi.org\/10.1007\/s11926-020-00921-8","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,26]]},"assertion":[{"value":"26 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"44"}}